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| INTRODUCTION
Antiphospholipid antibodies (aPL) have clinical significance due to their association with thrombosis, pregnancy morbidity, obstetrical complications, neurological issues, and cutaneous manifestations. 1 
Diagnosis of antiphospholipid syndrome (APS) is performed when clin-
ical laboratory examinations reveal the presence of persistent aPL in patients with appropriate clinical presentation, predominantly thrombosis or pregnancy morbidity.
2 When APS is diagnosed, anticoagulant therapy for a long-term period is considered due to the high risk of recurrent thrombosis. 3 Thus, accurate laboratory detection of aPL is critical. Solid phase assays are employed to detect two of the criteria antibodies, anti-cardiolipin antibodies (aCL) and anti-β2-glycoprotein I antibodies (aβ2GPI), whilst the other criterion antibody, lupus anticoagulant (LA), is detected in clotting time assays. Issues such as antibody heterogeneity, between-reagent and between-platform variability, and differences in raw data manipulation and interpretation, conspire to make standardization an elusive goal. Consequently, gold standard assays and reference plasmas are not yet established. 4, 5 While aCL and aβ2GPI assays can be calibrated to generate quantitative results in semi-arbitrary units to aid interpretation, a medley of phospholipid-dependent coagulation assays are employed for LA detection and the presence of LA is inferred or excluded from the result patterns obtained. This additional complexity to LA detection further complicates diagnosis and some LA guidelines with broad but not complete agreement are available to lead best practices.
6-8
There is no single test to detect all LA 1, [6] [7] [8] and guidelines recommend performance of two different tests that represent different assay principles, the diluted Russell's viper venom time (dRVVT) and a LA-sensitive activated partial thromboplastin time (APTT). [6] [7] [8] The assay medley for test types involves: (i) a screening test with low phospholipid concentration to find the effect of LA, (ii) mixing test in the screening test by a 1:1 mixture of index and normal pooled plasma (NPP) to show inhibition, and (iii) recapitulation of the screening test but with high phospholipid concentration to evidence phospholipid dependence as the confirm procedure. 6, 7 Mixing tests are important and useful in LA detection for the diagnosis because they can achieve differentiation between factor deficiency and the presence of an inhibitor, although the Clinical and Laboratory Standards Institute (CLSI) guideline supports initial performance of LA screening and confirmatory assays to show the phospholipid dependence of the antibody 8 and performance of mixing tests only when initial testing is not clear-cut.
Guidelines recommend mixing tests are interpreted with either a mixing test specific cut-off (MTC) or the index of circulating anticoagulant (ICA). In our previous study, we suggested that MTC had higher sensitivity than ICA for detection in the in vitro inhibition of LA. However, the study was performed with only one dAPTT and one dRVVT reagent. 9 Sensitivity and specificity of different APTT and dRVVT reagents to LA varies, predominantly due to differences in phospholipid composition and concentration. [10] [11] [12] Additionally, mixing plasma with NPP shows a dilution factor that can make weaker LA samples appear negative in the mixing test despite clear positivity in the screening and confirmation results on undiluted plasma, 7, 8, 13, 14 and a less sensitive reagent is therefore more likely to generate a falsenegative mixing test. The aim of the present study is to compare the LA diagnostic effectiveness of MTC and ICA by multiple APTT and dRVVT reagents.
| MATERIALS AND METHODS

| Plasma samples
The methods for blood collection and sample preparation were previously described. 9 We examined plasma samples from 105 non-anticoagulated patients who were LA-positive with routine diagnostic testing. 
| Coagulation screening tests
Factor deficiencies and undisclosed anticoagulation were excluded by performing coagulation screening tests prior to the LA assays.
APTT, prothrombin time (PT), thrombin time, and fibrinogen for Clauss method tests were measured by a Sysmex CS-2100i (Sysmex UK) 
| Mixing test
Normal and patient plasmas were mixed with NPP in a ratio of 1:1, and mixing tests were performed without incubation. CRYOcheck frozen Pooled Normal Plasma (Precision BioLogic Inc., Dartmouth, Canada) was used as the NPP. The mixing test ratios were calculated by dividing the clotting time of the mixture by that of the NPP to reflect the effect of any LA on the plasma in which it was mixed. 9 The
ICA was calculated as follows:
. 8 All mixing tests were performed on the CS-2400 (Sysmex Corporation) employing the automatic dilution function. All elevated screen ratios indicating that the known LA was reacting in a given alternative reagent were followed with a mixing test whose data were converted to normalised ratio and ICA.
| Reference intervals and cut-off values
Cut-off values for screen, confirm, and mixing test in each additional reagent were determined from upper limits of the distribution of 50 normal samples in each reagent, and for ICA with the routinely employed LA reagents, ICA cut-off values were previously established and used in each additional reagent. 9, [21] [22] [23] The normal donor plasmas were from sets of commercial frozen plasmas, Normal Donor Set (Precision BioLogic, Inc.).
| Statistical analysis
Data for the various parameters were compared using a Wilcoxon signed rank test, P-values below .01 were considered to be statistically significant. Reference intervals were calculated as the mean ± 2 standard deviations. 7, 8, 22, [24] [25] [26] [27] Shapiro-Wilk test was performed to confirm the Gaussian distribution of the reference intervals.
| RESULTS
| Cut-off values for each index and reagent
The cut-off values for screen ratio, mix ratio, ICA and confirm ratio for all reagents are shown in Table 2 . The confirm ratio of the four APTTs were calculated from the same Actin FS ratio. The population distributions for the normal donor samples were confirmed as Gaussian.
| Screen ratios, mix ratios, and ICA of LA positive samples in each reagent
Screen ratios of the 105 LA positive samples were calculated in each reagent. Mixing tests were performed on the samples and assays where LAs were detected in undiluted plasmas. Mix ratio and ICA were calculated in each reagent and samples were grouped according to whether they were mixing test-positive by both MTC and ICA, MTC only or negative in both MTC and ICA (Table 3 ). The range, mean, and median values of screen ratio in undiluted plasma are shown in each group.
Mean and median screen ratios were higher in samples positive by MTC and ICA than those positive by MTC alone in all reagents. There were no positive samples for inhibition by ICA alone in all reagents.
| Comparison of distribution in MTC and ICA
Mix ratio values for the groups of MTC-and ICA-positive, MTCpositive only, and MTC-and ICA-negative were compared (Figure 1 ). 
| Comparison of positivity in MTC and ICA
Frequencies of MTC and ICA positivity in samples that were LApositive in undiluted plasma are shown for each reagent (Table S1 ).
Overall 
| DISCUSSION
The present study compared detection rates of LA From screen and confirm data in undiluted plasma, between 33%
and 63% of samples were positive in APTT-based assays and 62%-70% in dRVVTs (Table 3) . This is a reflection of the well-described phenomena of antibody heterogeneity and reagent variability, 2, [6] [7] [8] [10] [11] [12] [26] [27] [28] [29] which at its most extreme, can result in a given dRVVT and APTT pairing detecting a particular antibody while another pairing would not.
Screen and mix ratios and ICA values were similar between the two dRVVT reagents, possibly due, at least in part, to normalizing the data reducing between reagent differences. 28, 29 More samples were positive in mixing tests when applying MTC than ICA in all reagents studied. In addition, there were no positive samples for inhibition by ICA alone in any reagent. Therefore, it was considered that MTC had higher sensitivity than ICA for detection in the in vitro inhibition of LA, as previously described with single APTT and dRVVT reagent pairings. 9, 30 The LA-sensitivity of a given reagent is a crucial contributor to the efficacy of mixing tests performed with it, and interpretation via MTC appears to enhance mixing test sensitivity. However, in situations where alternative or co-existing coagulation abnormalities are present, mixing tests can improve specificity of LA testing. [34] [35] [36] [37] While some authors contend that LA can be detected with integrated testing alone, even in situations such as anticoagulant therapy, 31, 36 other studies have evidenced improved diagnostic accuracy where initial analysis is not clear cut. 34, 38 The onus is on diagnostic practitioners to recognize when mixing tests can be omitted, and perform them where they will enhance interpretive and diagnostic outcomes. [7] [8] [9] 14, 26, 27, 34 Thus, it is valuable to maximise diagnostic efficacy of mixing tests, so for the present study, we specifically assessed mixing tests in the "ideal" situation of otherwise uncompromised samples. Cut-offs were generated using readily available statistical models from population distributions that are relatively easy to perform and recommended in guidelines as applicable to the routine diagnostic environment. [6] [7] [8] 25 Further work is planned to assess LA mixing tests in other situations, including anticoagulant therapy and factor deficiencies, in order to additionally apply Receiver Operator Characteristic (ROC) curve analysis to cut-off generation. 14, 32, 36 and the potency alone does not necessarily correlate with clinical significance and thrombotic risk. 37 , 39 We performed the LA assays in a clinically select and appropriate cohort, 53.3% of whom had established persistent LA.
Ellagic acid-based APTT reagents have been reported to have lower LA sensitivity than those employing silica as activator, 6, 40 although this has been questioned and is considered to be coincidental to the phospholipid composition of each reagent. (A) APTT & dAPTT SP, silica-based reagents. In the present study, performed on a much larger cohort of LA-containing plasmas, the percentage of LA detected in the FSL screening test was 57%, much higher than the 38% and 33%, respectively, of SP and SLA, and similar to that of Cephen and PTT silica-based reagents. In addition, positivity by both MTC and ICA was higher with FSL than all other reagents in the study. These data provide further evidence, in a large clinically appropriate population, that ellagic acid-based APTT reagents are not necessarily less effective than others in detecting LA.
In conclusion, our data indicate that MTC had higher sensitivity than ICA for detecting LA in multiple reagents. Whilst integrated testing can be diagnostically accurate and logistically attractive, there are situations where additionally undertaking mixing tests achieves accurate and more confident diagnoses. Although mixing tests introduce a dilution factor and may make weak LA samples appear negative, maximizing diagnostic capability of mixing tests for when they are needed, by applying the most sensitive interpretive index, improves the efficacy of LA detection.
